Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Also Sees Chance To Challenge Hemlibra
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
You may also be interested in...
Altuviiio May See Rapid Uptake Upon European Approval In Hemophilia A
Sanofi announced results from its XTEND-Kids trial, clearing the last requirement before an anticipated second half filing for Altuviiio’s approval with the EMA.
Sanofi’s Altuviiio Set To Reenergize Factor VIII Space
The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.
€1.5m Price Tag Could Spell EU Success For BioMarin’s Hemophilia Gene Therapy
The approval is a breakthrough for BioMarin, which is hoping to seize market share from Factor VIII replacement therapies and Roche’s Hemlibra.